ALY-201 (Alys Pharmaceuticals)

ALY-201 is a topical bispecific antibody developed by Alys Pharmaceuticals for the treatment of Chronic Spontaneous Urticaria (CSU). Originally part of the Granular Therapeutics pipeline before its acquisition by Alys, the candidate is designed to provide localized therapeutic effects by targeting two distinct pathways involved in the inflammatory response of urticaria. While the specific molecular targets have not been disclosed, the bispecific nature of the antibody suggests a multi-pronged approach to inhibiting the mast cell activation or cytokine signaling that drives CSU symptoms. The drug is intended for topical application, aiming to minimize systemic exposure while addressing the underlying immune-inflammatory drivers of the disease.